Zevra Therapeutics, Inc. (ZVRA) Market Cap & Valuation Ratios
Zevra Therapeutics, Inc. (ZVRA) has a market cap of $582.6M, a trailing P/E of 10.7 and a price-to-sales ratio of 4.3, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ZVRAZevra Therapeutics, Inc.Follow ZVRA — free
—
Price chart with a free account
- Market cap
- 582.6M
- P/E TTM
- 10.7
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| ZVRA | 0.6 | 10.7 | 2.7 | 4.3 | 5.6% | +119% | 61% | 68% |
| WVE | 0.6 | — | 4.0 | — | — | -30% | -333% | -255% |
| CADL | 0.6 | — | — | — | -9.3% | — | — | — |
| CRMD | 0.6 | 3.8 | 1.1 | 2.0 | — | +281% | 47% | 57% |
| SGMT | 0.6 | — | — | — | -7.0% | — | — | -59% |
| CLYM | 0.6 | — | — | — | -9.3% | — | — | -36% |
| IMMX | 0.6 | — | — | — | -6.7% | — | — | — |
| DBVT | 0.6 | — | 80.2 | — | — | +29% | — | — |
| MDXG | 0.6 | 97.8 | 1.3 | 5.7 | 7.8% | -2% | 2% | 4% |
| OLMA | 0.6 | — | — | — | — | — | — | -65% |
| ACRS | 0.6 | — | 56.0 | — | -11.3% | -51% | — | -82% |
| Median of these 10 | 50.8 | 4.0 | 3.9 | -8.2% | -2% | 2% | -59% |
P/E 10.7 vs. a peer median of 50.8; EV/Sales 2.7 vs. 4.0.
Growth vs. price
each dot a company · hover or tap for valuesWVE and CADL and SGMT and CLYM and IMMX and DBVT and OLMA and ACRS have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
Zevra Therapeutics, Inc. — questions
- What is Zevra Therapeutics, Inc.'s market cap?
- $582.6M.
- What is Zevra Therapeutics, Inc.'s P/E ratio?
- 10.7 on trailing twelve-month earnings to 2026-06-30.
- What is Zevra Therapeutics, Inc.'s price-to-sales ratio?
- 4.3.
Every figure on this page comes from Zevra Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.